object
semisynthet
deriv
glycopeptid
antibiot
shown
exert
vitro
antivir
activ
hiv
coronavirus
report
character
vitro
antihepat
c
viru
hcv
activ
sever
semisynthet
deriv
teicoplanin
aglycon
method
antihcv
activ
analys
three
differ
subgenom
hcv
replicon
system
use
luciferas
quantit
rtpcr
qrtpcr
assay
ii
infecti
hcv
cell
cultur
system
mean
qrt
pcr
immunofluoresc
assay
result
sever
teicoplanin
aglycon
deriv
elicit
select
antihcv
activ
replicon
well
infecti
cell
cultur
system
potent
deriv
prove
contrast
sever
directli
act
antivir
hcv
effici
clear
cell
replicon
combin
hcv
proteas
polymeras
inhibitor
overal
addit
effect
observ
likewis
equipot
wildtyp
replicon
well
replicon
resist
polymeras
proteas
inhibitor
follow
month
select
pressur
drugresist
replicon
select
combin
hcv
proteas
inhibitor
prevent
develop
variant
conclus
semisynthet
deriv
teicoplanin
aglycon
constitut
novel
class
hcv
replic
inhibitor
crossresist
variou
hcv
proteas
polymeras
inhibitor
particular
potent
clear
hepatoma
cell
replicon
class
molecul
also
provid
good
tool
obtain
novel
insight
replic
cycl
hcv
cellular
factorsprocess
crucial
viral
replic
hepat
c
viru
hcv
envelop
singlestrand
rna
viru
member
genu
hepaciviru
famili
flavivirida
worldwid
million
peopl
chronic
infect
hcv
thu
increas
risk
develop
seriou
lifethreaten
liver
diseas
current
standard
therapi
chronic
hepat
c
consist
combin
pegyl
interferon
ifn
ribavirin
unfortun
sustain
virolog
respons
therapi
limit
treat
patient
thu
urgent
need
new
treatment
strategi
one
promis
approach
develop
small
molecul
target
specif
enzymat
activ
associ
viral
nonstructur
ns
protein
inhibit
specif
interact
viral
protein
viral
cellular
cofactor
sever
select
inhibitor
includ
proteas
polymeras
inhibitor
clinic
develop
directli
act
antivir
hcv
rapid
emerg
mani
resist
variant
report
vitro
clinic
set
success
approach
limit
drug
resist
implement
ration
design
drug
combin
prerequisit
type
therapi
avail
multipl
select
drug
act
differ
target
glycopeptid
antibiot
ie
teicoplanin
vancomycin
use
treatment
gramposit
bacteri
infect
antibacteri
activ
glycopeptid
antibiot
result
inhibit
one
mechan
involv
synthesi
bacteri
cell
wall
ie
inhibit
membran
protein
involv
transglycosyl
interact
daladala
moieti
prevent
transpeptid
natur
glycopeptid
antibiot
report
exert
antivir
activ
semisynthet
deriv
prove
endow
antivir
activ
retroor
coronavirus
hiv
shown
semisynthet
aglycon
glycopeptid
potenti
interfer
viral
entri
process
compound
also
inhibit
coronaviru
replic
interf
earli
step
viral
life
cycl
report
vitro
antihcv
activ
aglycon
deriv
teicoplanin
novel
semisynthet
deriv
teicoplanin
aglycon
synthes
method
describ
dissolv
dmso
mass
spectral
data
electrospray
mass
spectrometri
present
figur
mass
spectral
data
compound
publish
recombin
ifna
intron
w
purchas
schere
plough
heistopdenberg
belgium
hcv
proteas
inhibitor
nucleosid
polymeras
inhibitor
azidocytidin
cmethylcytidin
nonnucleosid
polymeras
inhibitor
benzofuran
describ
highli
permiss
cell
line
huh
kindli
provid
dr
f
v
chisari
scripp
research
institut
la
jolla
cell
carri
hcv
replicon
huh
mono
wt
huh
huh
kindli
provid
professor
r
bartenschlag
univers
heidelberg
germani
cell
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
merelbek
belgium
supplement
heatinactiv
fetal
bovin
serum
integro
zaandam
netherland
nonessenti
amino
acid
iuml
penicillin
gibco
mgml
streptomycin
gibco
mgml
hygromycin
gibco
huh
mono
mgml
huh
mgml
huh
cell
cell
cultur
maintain
co
replicon
resist
panel
hcv
select
inhibitor
gener
previous
describ
antivir
assay
hcv
replicon
cell
antivir
assay
perform
describ
briefli
cell
seed
densiti
cell
per
well
cell
cultur
plate
dmem
contain
mgml
mgml
mgml
hygromycin
huh
huh
huh
mono
cell
respect
co
h
incub
medium
replac
fresh
dmem
without
serial
dilut
test
compound
replicon
rna
level
determin
revers
transcript
quantit
pcr
qrtpcr
huh
cell
hcv
replic
quantifi
measur
firefli
luciferas
activ
cell
cultur
plate
safir
tecan
austria
highli
infecti
hcv
describ
delgrang
et
al
use
antivir
assay
total
huh
cell
per
well
cell
cultur
plate
incub
viru
specif
infect
specif
infect
ratio
hcv
rna
copi
number
focusform
unit
per
ml
time
serial
dilut
compound
follow
day
incub
medium
remov
cell
wash
lyse
extract
intracellular
rna
hcv
rna
quantifi
mean
qrtpcr
cell
seed
densiti
cell
per
well
cell
cultur
plate
dmem
hygromycin
repliconcontain
cell
follow
overnight
incub
co
medium
replac
fresh
dmem
without
hygromycin
contain
serial
dilut
test
compound
day
incub
cell
viabil
determin
mean
mtspm
promega
immunofluoresc
assay
naiv
huh
cell
seed
eightwel
chamber
slide
labtek
ii
nunc
germani
densiti
cellswel
next
day
cultur
inocul
viral
stock
specif
infect
follow
h
incub
inoculum
remov
cell
wash
three
time
incub
h
cell
stain
rabbit
polyclon
antihcv
antibodi
kindli
provid
professor
bartenschlag
univers
heidelberg
germani
secondari
antibodi
alexa
fluor
w
invitrogen
follow
dapi
stain
cultur
visual
use
confoc
laser
scan
microscop
lcsm
leica
microsystem
germani
effect
drug
combin
name
togeth
hcv
proteas
polymeras
inhibitor
evalu
chequerboard
format
use
method
prichard
shipman
theoret
addit
effect
calcul
doserespons
curv
individu
compound
equat
z
x
x
repres
inhibit
produc
alon
inhibit
second
compound
alon
z
repres
effect
produc
combin
second
compound
theoret
addit
surfac
subtract
actual
experiment
surfac
result
horizont
surfac
equal
zero
plane
combin
addit
surfac
lie
zero
plane
indic
synergist
effect
combin
surfac
zero
plane
indic
antagon
combin
three
independ
experi
carri
measur
doserespons
curv
individu
compound
combin
assay
carri
describ
briefli
huh
replicon
carri
neomycin
gene
cultur
consecut
obeid
et
al
passag
presenc
absenc
antivir
drug
without
addit
cultur
medium
clearanc
phase
next
cell
cultur
absenc
antivir
compound
presenc
rebound
phase
principl
cell
lose
replicon
clearanc
phase
die
rebound
phase
wherea
cell
replicon
complet
clear
abl
surviv
presenc
huh
cell
seed
densiti
cell
per
well
cell
cultur
plate
complet
dmem
mgml
presenc
mm
mm
combin
either
reach
confluenc
cell
trypsin
seed
new
cell
cultur
plate
condit
follow
seven
passag
select
half
cultur
fix
stain
giemsa
remain
cultur
store
use
divers
librari
small
molecul
contain
semisynthet
glycopeptid
antibiot
ie
semisynthet
deriv
teicoplanin
figur
eremomycin
vancomycin
screen
subgenom
hcv
system
genotyp
none
vancomycin
deriv
inhibit
subgenom
hcv
replic
wherea
one
eremomycin
deriv
effect
concentr
ec
mm
cytostat
concentr
cc
mm
data
shown
particular
sever
teicoplanin
aglycon
analogu
found
inhibit
hcv
replicon
replic
three
differ
subgenom
replicon
system
nontox
concentr
tabl
potent
analogu
first
seri
compound
evalu
tabl
ec
valu
rang
mm
sinc
teicoplanin
known
high
bind
affin
serum
protein
evalu
effect
human
serum
antihcv
activ
presenc
human
serum
albumin
increas
ec
valu
observ
data
shown
specif
antihcv
activ
infecti
hcv
system
panel
structur
close
relat
deriv
seri
figur
next
evalu
effect
hcv
replic
molecul
inhibit
hcv
replic
concentrationdepend
manner
among
other
slightli
efficaci
figur
structur
formula
teicoplanin
aglycon
deriv
novel
potent
hcv
potent
inhibitor
ec
mm
respect
figur
tabl
antivir
activ
select
caus
advers
effect
host
cell
concentr
mm
hcv
replic
inhibit
mm
wherea
host
cell
metabol
slightli
affect
concentr
inhibitori
effect
corrobor
monitor
effect
express
viral
protein
hcv
figur
also
inhibit
vitro
replic
yellow
fever
viru
dengu
viru
type
low
micromolar
concentr
replic
bovin
viral
diarrhoea
viru
anoth
member
famili
flavivirida
combin
interferon
proteas
polymeras
inhibitor
result
addit
antivir
effect
antivir
efficaci
combin
ifn
proteas
inhibitor
polymeras
inhibitor
azidocytidin
evalu
day
antivir
assay
huh
cell
chequerboard
format
combin
analys
method
prichard
shipman
combin
result
addit
antivir
effect
figur
experi
set
studi
whether
abl
clear
repliconcontain
cell
huh
hcv
replicon
huh
cell
treat
four
consecut
passag
proteas
inhibitor
polymeras
hcvcc
infecti
hcv
cell
cultur
system
data
express
mm
meanssd
three
four
independ
experi
obeid
et
al
inhibitor
cmethylcytidin
cmc
azidocytidin
ec
either
alon
combin
proteas
polymeras
inhibitor
use
alon
reduc
hcv
rna
replic
log
tabl
figur
fail
clear
cell
replicon
even
follow
four
consecut
passag
contrast
alon
also
combin
inhibitor
result
effici
inhibit
viral
replic
studi
whether
replicon
resist
hcv
proteas
polymeras
inhibitor
remain
suscept
shown
tabl
prove
equipot
wildtyp
replicon
well
panel
replicon
resist
proteas
inhibitor
nucleosid
polymeras
inhibitor
cmethylcytidin
nonnucleosid
polymeras
inhibitor
replicon
teicoplanin
aglycon
analogu
prevent
develop
hcv
replicon
resist
proteas
inhibitor
studi
whether
abl
delay
even
prevent
resist
develop
hcv
replicon
proteas
inhibitor
huh
repliconcontain
cell
cultur
seven
consecut
passag
presenc
either
mm
alon
drugresist
replicon
readili
select
assess
passag
howev
combin
mm
coloni
develop
tabl
result
advers
effect
host
cell
sinc
chang
morpholog
densiti
observ
parallel
control
cultur
treat
antivir
molecul
absenc
pressur
none
cultur
also
treat
mm
coloni
develop
passag
combin
thu
complet
clear
cell
replicon
suppress
emerg
drugresist
variant
glycopeptid
antibiot
vancomycin
teicoplanin
wide
use
often
lastresort
treatment
gramposit
bacteri
infect
inhibit
bacteri
cell
wall
biosynthesi
form
noncoval
complex
bacteri
peptidoglycan
precursor
common
structur
share
among
glycopeptid
ie
heptapeptid
core
crucial
antibacteri
activ
sheer
size
complex
novel
potent
hcv
potent
inhibitor
structur
facilit
numer
chemic
biochem
modif
although
alway
straightforward
synthesi
analogu
pharmacophor
analysi
reveal
substructur
implic
antihcv
activ
may
reduc
lead
smaller
molecul
delin
substructur
within
glycopeptid
may
serv
focal
point
chemic
modif
analogu
seri
figur
almost
activ
parent
compound
tabl
figur
argu
major
role
teicoplanin
peptid
scaffold
chemic
modif
may
also
help
optim
pharmacolog
properti
class
molecul
chemic
modif
vancomycin
result
exampl
develop
oritavancin
molecul
long
halflif
h
distribut
exampl
liver
limit
oral
avail
glycopeptid
overcom
formul
exampl
vancomycin
liposom
solidst
emuls
sinc
neither
virus
mammalian
host
cell
produc
peptidoglycan
mechan
action
antibiot
inhibitori
activ
virus
certainli
differ
definit
clearancerebound
huh
replicon
assay
repliconcontain
cell
treat
two
four
consecut
passag
black
bar
white
bar
top
panel
cmethylcytidin
middl
panel
azidocytidin
bottom
panel
combin
select
hcv
inhibitor
grey
bar
compound
concentr
ec
clearanc
phase
c
cell
incub
compound
presenc
absenc
clearanc
phase
cell
cultur
twice
fresh
medium
contain
mgml
without
antivir
agent
rebound
phase
r
intracellular
hcv
rna
surviv
cell
quantifi
qrtpcr
utc
untreat
control
cx
clearanc
phase
passag
x
rx
rebound
phase
passag
x
cxrx
rebound
follow
clearanc
x
obeid
et
al
mechan
bacteria
aglycon
glycopeptid
antibiot
target
entri
hiv
earli
step
replic
cycl
coronavirus
fact
molecul
inhibit
entri
virus
necessarili
mean
mechan
hcv
must
similar
geneticin
exampl
shown
inhibit
pestiviru
assembl
releas
replic
translat
flavivirus
even
though
virus
belong
famili
flavivirida
inhibit
two
differ
mechan
demonstr
unlik
case
hiv
coronavirus
inhibit
hcv
replic
postentri
event
inde
molecul
inhibit
replic
hcv
subgenom
replicon
encod
structur
protein
activ
replicon
compar
infecti
hcv
system
furthermor
still
activ
ad
hcvinfect
cultur
whether
inhibit
intracellular
replic
result
direct
interact
viral
protein
mediat
interfer
host
cell
factor
remain
elucid
far
abl
select
drugresist
variant
despit
sever
month
attempt
interestingli
oritavancin
shown
interfer
intracellular
cholesterol
phospholipid
metabol
membran
organ
permeabl
host
cell
lipid
metabol
membran
organ
import
hcv
replic
thu
possibl
might
target
cellular
factor
essenti
hcv
replic
ii
influenc
cell
lipid
metabol
way
counteract
hcv
replic
disturb
membran
organ
import
hcv
replic
cycl
subgenom
replicon
model
effici
clear
cell
hcv
replicon
proteas
polymeras
inhibitor
concentr
test
figur
futur
hcv
therapi
consist
combin
two
select
inhibitor
line
aim
studi
combin
effect
either
ifn
hcv
inhibitor
proteas
polymeras
inhibitor
combin
result
overal
addit
antivir
effect
figur
henc
compound
probabl
interfer
mechan
action
select
inhibitor
support
observ
equipot
wildtyp
replicon
replicon
resist
variou
inhibitor
proteas
nucleosid
nonnucleosid
polymeras
delay
prevent
resist
develop
replicon
proteas
inhibitor
importantli
even
month
continu
cultur
presenc
suboptim
concentr
hcv
replicon
reduc
suscept
emerg
barrier
resist
class
compound
might
therefor
high
assum
hcv
quasispeci
equal
divers
vitro
vivo
conclus
aglycon
analogu
teicoplanin
inhibit
vitro
hcv
replic
particular
potent
clear
hepatoma
cell
replicon
explor
structureact
relationship
may
lead
develop
highli
potent
inhibitor
hcv
replic
moreov
class
molecul
also
provid
good
tool
obtain
novel
insight
replic
cycl
hcv
cellular
factorsprocess
crucial
viral
replic
novel
potent
hcv
potent
inhibitor
